• +1-646-491-9876
    • +91-20-67278686

    Search

    Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2015

    Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2015

    • Report Code ID: RW0001172420
    • Category Pharmaceuticals
    • No. of Pages 114
    • Publication Month Jan-15
    • Publisher Name Global Markets Direct
    Hospital Acquired Pneumonia (HAP)-Pipeline Review, H1 2015

    Summary

    Publisher's, 'Hospital Acquired Pneumonia (HAP)-Pipeline Review, H1 2015', provides an overview of the Hospital Acquired Pneumonia (HAP)'s therapeutic pipeline.

    This report provides comprehensive information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP) and special features on late-stage and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

    The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

    Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

    Scope

    - The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP)
    - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in the therapeutics development for Hospital Acquired Pneumonia (HAP) and enlists all their major and minor projects
    - The report summarizes all the dormant and discontinued pipeline projects
    - A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - A detailed assessment of monotherapy and combination therapy pipeline projects
    - Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of target, MoA, route of administration and molecule type
    - Latest news and deals relating related to pipeline products

    Reasons to buy

    - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP)
    - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
    - Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    Table of Contents
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Global Markets Direct Report Coverage 7
    Hospital Acquired Pneumonia (HAP) Overview 8
    Therapeutics Development 9
    Pipeline Products for Hospital Acquired Pneumonia (HAP)-Overview 9
    Pipeline Products for Hospital Acquired Pneumonia (HAP)-Comparative Analysis 10
    Hospital Acquired Pneumonia (HAP)-Therapeutics under Development by Companies 11
    Hospital Acquired Pneumonia (HAP)-Therapeutics under Investigation by Universities/Institutes 13
    Hospital Acquired Pneumonia (HAP)-Pipeline Products Glance 14
    Late Stage Products 14
    Clinical Stage Products 15
    Early Stage Products 16
    Unknown Stage Products 17
    Hospital Acquired Pneumonia (HAP)-Products under Development by Companies 18
    Hospital Acquired Pneumonia (HAP)-Products under Investigation by Universities/Institutes 20
    Hospital Acquired Pneumonia (HAP)-Companies Involved in Therapeutics Development 21
    Achaogen Inc. 21
    Adenium Biotech ApS 22
    AstraZeneca PLC 23
    Cardeas Pharma Corp. 24
    Cubist Pharmaceuticals, Inc. 25
    Dong-A Socio Group 26
    F. Hoffmann-La Roche Ltd. 27
    KaloBios Pharmaceuticals, Inc. 28
    MedImmune, LLC 29
    Meiji Seika Pharma Co., Ltd. 30
    Melinta Therapeutics, Inc 31
    Nabriva Therapeutics AG 32
    Savara Inc. 33
    Serendex Pharmaceuticals A/S 34
    Tetraphase Pharmaceuticals Inc. 35
    Hospital Acquired Pneumonia (HAP)-Therapeutics Assessment 36
    Assessment by Monotherapy Products 36
    Assessment by Combination Products 37
    Assessment by Target 38
    Assessment by Mechanism of Action 40
    Assessment by Route of Administration 42
    Assessment by Molecule Type 44
    Drug Profiles 46
    (amikacin + fosfomycin)-Drug Profile 46
    Product Description 46
    Mechanism of Action 46
    R&D Progress 46
    (ceftazidime + avibactam sodium)-Drug Profile 48
    Product Description 48
    Mechanism of Action 48
    R&D Progress 48
    (ceftolozane sulfate + tazobactam sodium)-Drug Profile 50
    Product Description 50
    Mechanism of Action 50
    R&D Progress 50
    AA-139-Drug Profile 52
    Product Description 52
    Mechanism of Action 52
    R&D Progress 52
    arbekacin-Drug Profile 54
    Product Description 54
    Mechanism of Action 54
    R&D Progress 54
    delafloxacin-Drug Profile 55
    Product Description 55
    Mechanism of Action 55
    R&D Progress 55
    eravacycline-Drug Profile 58
    Product Description 58
    Mechanism of Action 58
    R&D Progress 58
    fosfomycin-Drug Profile 60
    Product Description 60
    Mechanism of Action 60
    R&D Progress 60
    KB-001A-Drug Profile 61
    Product Description 61
    Mechanism of Action 61
    R&D Progress 61
    lefamulin-Drug Profile 62
    Product Description 62
    Mechanism of Action 62
    R&D Progress 62
    MEDI-3902-Drug Profile 64
    Product Description 64
    Mechanism of Action 64
    R&D Progress 64
    MEDI-4893-Drug Profile 65
    Product Description 65
    Mechanism of Action 65
    R&D Progress 65
    molgramostim-Drug Profile 67
    Product Description 67
    Mechanism of Action 67
    R&D Progress 67
    Nu-2-Drug Profile 69
    Product Description 69
    Mechanism of Action 69
    R&D Progress 69
    plazomicin sulfate-Drug Profile 70
    Product Description 70
    Mechanism of Action 70
    R&D Progress 70
    pseudomonas aeruginosa vaccine-Drug Profile 72
    Product Description 72
    Mechanism of Action 72
    R&D Progress 72
    pseudomonas and VAP conjugate vaccine-Drug Profile 73
    Product Description 73
    Mechanism of Action 73
    R&D Progress 73
    Qn-2251-Drug Profile 74
    Product Description 74
    Mechanism of Action 74
    R&D Progress 74
    RG-7929-Drug Profile 75
    Product Description 75
    Mechanism of Action 75
    R&D Progress 75
    tedizolid phosphate-Drug Profile 76
    Product Description 76
    Mechanism of Action 76
    R&D Progress 76
    vancomycin hydrochloride-Drug Profile 79
    Product Description 79
    Mechanism of Action 79
    R&D Progress 79
    Hospital Acquired Pneumonia (HAP)-Recent Pipeline Updates 81
    Hospital Acquired Pneumonia (HAP)-Dormant Projects 105
    Hospital Acquired Pneumonia (HAP)-Discontinued Products 106
    Hospital Acquired Pneumonia (HAP)-Product Development Milestones 107
    Featured News & Press Releases 107
    Jan 08, 2015: Achaogen Announces Plazomicin Granted QIDP Designation by FDA 107
    Oct 03, 2013: Tetraphase to Present New Data at IDWeek on Eravacycline's Potential Activity in Treating Serious Respiratory Infections 107
    Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013 108
    May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 110
    May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 110
    Jan 07, 2013: Trius Therapeutics's Tedizolid Receives Qualified Infectious Disease Product Designation From FDA 111
    Dec 06, 2012: Cubist Pharma's Antibiotic Candidate Ceftolozane Obtains QIDP Designation From FDA 111
    Appendix 113
    Methodology 113
    Coverage 113
    Secondary Research 113
    Primary Research 113
    Expert Panel Validation 113
    Contact Us 113
    Disclaimer 114

    List of Tables
    Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2015 9
    Number of Products under Development for Hospital Acquired Pneumonia (HAP)-Comparative Analysis, H1 2015 10
    Number of Products under Development by Companies, H1 2015 12
    Number of Products under Investigation by Universities/Institutes, H1 2015 13
    Comparative Analysis by Late Stage Development, H1 2015 14
    Comparative Analysis by Clinical Stage Development, H1 2015 15
    Comparative Analysis by Early Stage Development, H1 2015 16
    Comparative Analysis by Unknown Stage Development, H1 2015 17
    Products under Development by Companies, H1 2015 18
    Products under Development by Companies, H1 2015 (Contd..1) 19
    Products under Investigation by Universities/Institutes, H1 2015 20
    Hospital Acquired Pneumonia (HAP)-Pipeline by Achaogen Inc., H1 2015 21
    Hospital Acquired Pneumonia (HAP)-Pipeline by Adenium Biotech ApS, H1 2015 22
    Hospital Acquired Pneumonia (HAP)-Pipeline by AstraZeneca PLC, H1 2015 23
    Hospital Acquired Pneumonia (HAP)-Pipeline by Cardeas Pharma Corp., H1 2015 24
    Hospital Acquired Pneumonia (HAP)-Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 25
    Hospital Acquired Pneumonia (HAP)-Pipeline by Dong-A Socio Group, H1 2015 26
    Hospital Acquired Pneumonia (HAP)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 27
    Hospital Acquired Pneumonia (HAP)-Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 28
    Hospital Acquired Pneumonia (HAP)-Pipeline by MedImmune, LLC, H1 2015 29
    Hospital Acquired Pneumonia (HAP)-Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015 30
    Hospital Acquired Pneumonia (HAP)-Pipeline by Melinta Therapeutics, Inc, H1 2015 31
    Hospital Acquired Pneumonia (HAP)-Pipeline by Nabriva Therapeutics AG, H1 2015 32
    Hospital Acquired Pneumonia (HAP)-Pipeline by Savara Inc., H1 2015 33
    Hospital Acquired Pneumonia (HAP)-Pipeline by Serendex Pharmaceuticals A/S, H1 2015 34
    Hospital Acquired Pneumonia (HAP)-Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 35
    Assessment by Monotherapy Products, H1 2015 36
    Assessment by Combination Products, H1 2015 37
    Number of Products by Stage and Target, H1 2015 39
    Number of Products by Stage and Mechanism of Action, H1 2015 41
    Number of Products by Stage and Route of Administration, H1 2015 43
    Number of Products by Stage and Molecule Type, H1 2015 45
    Hospital Acquired Pneumonia (HAP) Therapeutics-Recent Pipeline Updates, H1 2015 81
    Hospital Acquired Pneumonia (HAP)-Dormant Projects, H1 2015 105
    Hospital Acquired Pneumonia (HAP)-Discontinued Products, H1 2015 106

    List of Figures
    Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2015 9
    Number of Products under Development for Hospital Acquired Pneumonia (HAP)-Comparative Analysis, H1 2015 10
    Number of Products under Development by Companies, H1 2015 11
    Comparative Analysis by Clinical Stage Development, H1 2015 15
    Comparative Analysis by Early Stage Products, H1 2015 16
    Assessment by Monotherapy Products, H1 2015 36
    Assessment by Combination Products, H1 2015 37
    Number of Products by Top 10 Targets, H1 2015 38
    Number of Products by Stage and Top 10 Targets, H1 2015 38
    Number of Products by Top 10 Mechanism of Actions, H1 2015 40
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 40
    Number of Products by Top 10 Routes of Administration, H1 2015 42
    Number of Products by Stage and Top 10 Routes of Administration, H1 2015 42
    Number of Products by Top 10 Molecule Types, H1 2015 44
    Number of Products by Stage and Top 10 Molecule Types, H1 2015 44
    Achaogen Inc.
    Adenium Biotech ApS
    AstraZeneca PLC
    Cardeas Pharma Corp.
    Cubist Pharmaceuticals, Inc.
    Dong-A Socio Group
    F. Hoffmann-La Roche Ltd.
    KaloBios Pharmaceuticals, Inc.
    MedImmune, LLC
    Meiji Seika Pharma Co., Ltd.
    Melinta Therapeutics, Inc
    Nabriva Therapeutics AG
    Savara Inc.
    Serendex Pharmaceuticals A/S
    Tetraphase Pharmaceuticals Inc.

    Request for Sample

    Report Url https://www.reportsweb.com//hospital-acquired-pneumonia-hap-pipeline-review-h1-2015&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//hospital-acquired-pneumonia-hap-pipeline-review-h1-2015&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//hospital-acquired-pneumonia-hap-pipeline-review-h1-2015&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments